Endothelin-Converting Enzymes

Metalloendopeptidases which convert BIG ENDOTHELIN to ENDOTHELIN-1.

Also Known As:

ECE-1beta; Endothelin Converting Enzyme; Endothelin Converting Enzyme-1a; Endothelin-Converting Enzyme; Endothelin-Converting Enzyme 1; Endothelin-Converting Enzyme 2; Endothelin-Converting Enzyme II; Endothelin-Converting Enzyme-1b; Endothelin-Converting Metalloprotease 2; Metalloprotease ECE-2; ECE-2, Metalloprotease; Endothelin Converting Enzyme 1; Endothelin Converting Enzyme 1a; Endothelin Converting Enzyme 1b; Endothelin Converting Enzyme 2; Endothelin Converting Enzyme II; Endothelin Converting Enzymes; Endothelin Converting Metalloprotease 2; Metalloprotease ECE 2

Networked: 165 relevant articles (6 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jeng, Arco Y: 9 articles (11/2010 - 08/2002)
2.	Kwan, Aij-Lie: 6 articles (03/2007 - 08/2002)
3.	Hocher, Berthold: 4 articles (06/2011 - 11/2004)
4.	Ikura, Yoshihiro: 4 articles (03/2008 - 05/2004)
5.	Naruko, Takahiko: 4 articles (03/2008 - 05/2004)
6.	Tanzawa, Kazuhiko: 4 articles (03/2008 - 01/2003)
7.	Ueda, Makiko: 4 articles (03/2008 - 05/2004)
8.	Kassell, Neal F: 4 articles (03/2007 - 08/2002)
9.	Wu, Shu-Chuan: 4 articles (03/2007 - 08/2002)
10.	Love, Seth: 3 articles (01/2017 - 11/2011)

Related Diseases

1.	Muscle Spasticity (Spastic) 04/01/2003 - "However, relaxations to chelerythrine were not significantly greater in endothelin-1 constricted spastic vessels initially relaxed with the endothelin converting enzyme inhibitor, phosphoramidon, as compared to endothelin-1 constricted control vessels. " 06/01/2002 - "However, relaxations to Y-27632 were not significantly greater in endothelin-1 constricted spastic vessels initially relaxed with the endothelin converting enzyme inhibitor, phosphoramidon, as compared to endothelin-1 constricted control vessels. "
2.	Hypertension (High Blood Pressure) 09/29/2009 - "Recent studies have identified a polymorphism in the endothelin-converting enzyme (ECE)-1b promoter (-338C/A) that is strongly associated with hypertension in women. " 08/01/1998 - "The hypotensive effects of endothelin converting enzyme inhibitors and endothelin receptor antagonists should be useful in the treatment of hypertension and related diseases. " 09/01/2013 - "Combined endothelin-converting enzyme and neutral endopeptidase inhibition could provide a new approach to hypertension in this high-risk population. " 10/01/2000 - "The results of experimental and human studies with antagonists of endothelin receptors and endothelin-converting enzyme blockers also support the role of endothelin in the pathogenesis of hypertension. " 01/01/2022 - "Endothelin-1 (ET-1), the most potent endogenous vasoconstrictor, generated by enzymatic cleavage catalyzed by an endothelin-converting enzyme (ECE), plays a significant role in the regulation of hypertension. "
3.	Ischemia 01/01/2022 - "Prophylactic exercise-derived circulating exosomal miR-125a-5p promotes endogenous revascularization after hindlimb ischemia by targeting endothelin converting enzyme 1." 02/01/2011 - "As ET-1 is generated from big ET-1 via endothelin-converting enzyme (ECE), ischemia/reperfusion-induced cardiac injury may be exacerbated by exogenous big ET-1. " 05/01/2011 - "We have recently shown that an appropriate amount of exogenous big endothelin-1 (ET-1) has beneficial effects on ischemia-/reperfusion-induced norepinephrine overflow and cardiac dysfunction in rat hearts and that these effects occur through a conversion to ET-1 by endothelin-converting enzyme and following stimulation of ETB receptor. " 09/04/2008 - "The aim of this study was to investigate the role of endogenously generated endothelin-1 in ischemia/reperfusion-induced norepinephrine overflow and cardiac dysfunction using a nonselective prototype of endothelin-converting enzyme (ECE) inhibitor, phosphoramidon, and a selective ECE inhibitor, SM-19712 (4-chloro-N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl]benzenesulfonamide, monosodium salt). " 10/01/1998 - "In this study, the effects of BQ123 (an ET(A) receptor antagonist), bosentan (a nonselective ET(A)-ET(B) antagonist), and phosphoramidon (an endothelin converting enzyme inhibitor) were investigated on intestinal mucosal lesion formation and changes in tissue PGE2 and LTC4 levels due to intestinal ischemia-reperfusion (I/R) injury in rats. "
4.	Pulmonary Hypertension 09/01/2003 - "We hypothesized that increased ET-1 levels induce pulmonary hypertension during group B Streptococcus (GBS) infusion, and this can be attenuated by the administration of an endothelin-converting enzyme inhibitor (ECEI). " 09/01/2003 - "The role of endothelin converting enzyme inhibition during group B streptococcus-induced pulmonary hypertension in newborn piglets." 11/01/1999 - "ET-1 has been noted in high concentrations in some clinical cases and experimental models of pulmonary hypertension, coupled with ET-1 receptors' modulation and altered endothelin converting enzyme activities, suggesting their active role in both arteriolar vasoconstriction and occlusion. " 08/01/1995 - "Blockade of endothelin-converting enzyme reduces pulmonary hypertension after cardiopulmonary bypass and circulatory arrest." 07/01/2008 - "[Chronic theatment with an endothelin-converting enzyme inhibitor reduces the development of hypoxia-induced pulmonary hypertension in rat]."
5.	Reperfusion Injury 07/01/2001 - "Protective role of an endothelin-converting enzyme inhibitor (FR901533) in hepatic ischemia/reperfusion injury." 01/01/1997 - "Phosphoramidon, an endothelin converting enzyme inhibitor attenuates local gastric ischemia-reperfusion injury in rats." 01/01/1997 - "We have investigated the effects of endothelin converting enzyme inhibition on local gastric ischemia-reperfusion injury in rats by using two metalloprotease inhibitors, phosphoramidon and thiorphan. " 11/01/2002 - "To evaluate the effect of the combination of N-acetylcysteine (NAC), a potent antioxidant, sodium nitroprusside (SNP), a nitric oxide donor, and phosphoramidon (P), an endothelin converting enzyme inhibitor, on tissue protection against ischemia-reperfusion injury, we studied the biochemical and morphological changes due to 90 min of renal ischemia-reperfusion in the rat model. "

Related Drugs and Biologics

1.	phosphoramidon
2.	Endothelin-1 (Endothelin 1)
3.	Neprilysin (Neutral Endopeptidase)
4.	Endothelin Receptor Antagonists
5.	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)
6.	chelerythrine
7.	Nitric Oxide Donors
8.	Nitroprusside (Sodium Nitroprusside)
9.	Antioxidants
10.	Acetylcysteine (Siran)

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Microspheres (Microsphere)
3.	Percutaneous Coronary Intervention
4.	Immunomodulation
5.	Therapeutics